Virulence determinants of equine infectious anemia virus

Current HIV Research

Volumn 8, Issue 1, 2010, Pages 66-72

  Payne, Susan L ^a   Fuller, Frederick J ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN;

EQUINE INFECTIOUS ANEMIA VIRUS; GENE MAPPING; NONHUMAN; RETROVIRUS INFECTION; REVIEW; VIRAL GENETICS; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS VIRULENCE;

ANIMALS; DISEASE MODELS, ANIMAL; EQUINE INFECTIOUS ANEMIA; HORSES; HOST-PATHOGEN INTERACTIONS; INFECTIOUS ANEMIA VIRUS, EQUINE; MACROPHAGES; TERMINAL REPEAT SEQUENCES; VIRAL TROPISM; VIRULENCE FACTORS; VIRUS REPLICATION;

EID: 77949661291     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210790416352     Document Type: Review

References (41)

1. Montelaro RC, Ball JM, Rushlow KE. Equine retroviruses, In: Levy JA, Ed. The Retroviridae. New York and London: Plenum Press 1993: pp. 257-360.
2. Payne S, Lim W-S, Fuller FJ, Ball JM. Equine infectious anemia virus as a model for lentiviral pathogenesis, In: Friedman H, Specter S, Bendinelli M, Eds. In vivo models of hiv disease and control. New York: Springer 2006; pp. 365-90.
3. Payne SL, Rausch J, Rushlow K, et al. Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol 1994; 75(Pt 2): 425-9.
4. Payne SL, Qi XM, Shao H, Dwyer A, Fuller FJ. Disease induction by virus derived from molecular clones of equine infectious anemia virus. J Virol 1998; 72(1): 483-7.
5. Payne SL, Pei XF, Jia B, Fagerness A, Fuller FJ. Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus. J Virol 2004; 78(5): 2478-85.
6. Payne SL, Elder JH. The role of retroviral dUTPases in replication and virulence. Curr Protein Pepti Sci 2001; 2(4): 381-388.
7. Elder JH, Lerner DL, Hasselkus-Light CS, et al. Distinct subsets of retroviruses encode dUTPase. J Virol 1992; 66(3): 1791-1794.
8. Rushlow K, Olsen K, Stiegler G, Payne SL, Montelaro RC, Issel CJ. Lentivirus genomic organization: the complete nucleotide sequence of the env gene region of equine infectious anemia virus. Vir 1986; 155(2): 309-21.
9. Taube R, Fujinaga K, Irwin D, Wimmer J, Geyer M, Peterlin BM. Interactions between equine cyclin T1, Tat, and TAR are disrupted by a leucine-to-valine substitution found in human cyclin T1. J Virol 2000; 74(2): 892-8.
10. Derse D, Newbold SH. Mutagenesis of EIAV TAT reveals structural features essential for transcriptional activation and TAR element recognition. Virology 1993; 194(2): 530-6.
11. Derse D, Carvalho M, Carroll R, Peterlin BM. A minimal lentivirus Tat. J Virol 1991; 65(12): 7012-5.
12. Carvalho M, Derse D. Mutational analysis of the equine infectious anemia virus Tat-responsive element. J Virol 1991; 65(7): 3468-74.
13. Mancuso VA, Hope TJ, Zhu L, Derse D, Phillips T, Parslow TG. Posttranscriptional effector domains in the Rev proteins of feline immunodeficiency virus and equine infectious anemia virus. J Virol 1994; 68(3): 1998-2001.
14. Fridell RA, Partin KM, Carpenter S, Cullen BR. Identification of the activation domain of equine infectious anemia virus rev. J Virol 1993; 67(12): 7317-23.
15. Li F, Puffer BA, Montelaro RC. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 1998; 72(10): 8344-8.
16. Li F, Leroux C, Craigo JK, Cook SJ, Issel CJ, Montelaro RC. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. J Virol 2000; 74(1): 573-9.
17. Fagerness AJ, Flaherty MT, Perry ST, Jia B, Payne SL, Fuller FJ. The S2 accessory gene of equine infectious anemia virus is essential for expression of disease in ponies. Virology 2006; 349(1): 22-30.
18. Whetter L, Archambault D, Perry S, et al. Equine infectious anemia virus derived from a molecular clone persistently infects horses. J Virol 1990; 64(12): 5750-6.
19. Cook RF, Leroux C, Cook SJ et al. Development and characterization of an in vivo pathogenic molecular clone of equine infectious anemia virus. J Virol 1998; 72(2): 1383-93.
20. Mealey RH, Leib SR, Pownder SL, McGuire TC. Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection. J Virol 2004; 78(17): 9295-305.
21. Ball JM, Swaggerty CL, Pei X, et al. SU proteins from virulent and avirulent EIAV demonstrate distinct biological properties. Virology 2005; 333(1): 132-44.
22. Lim WS, Payne SL, Edwards JF, Kim I, Ball JM. Differential effects of virulent and avirulent equine infectious anemia virus on macrophage cytokine expression. Virology 2005; 332(1): 295-306.
23. Payne SL, La Celle K, Pei XF, et al. Long terminal repeat sequences of equine infectious anaemia virus are a major determinant of cell tropism. J Gen Virol 1999; 80(Pt 3): 755-9.
24. Maury W, Perryman S, Oaks JL, et al. Localized sequence heterogeneity in the long terminal repeats of in vivo isolates of equine infectious anemia virus. J Virol 1997; 71(7): 4929-37.
25. Lichtenstein DL, Craigo JK, Leroux C, et al. Effects of long terminal repeat sequence variation on equine infectious anemia virus replication in vitro and in vivo. Virology 1999; 263(2): 408-17.
26. Hines R, Sorensen BR, Shea MA, Maury W. PU.1 Binding to ets Motifs within the Equine Infectious Anemia Virus Long Terminal Repeat (LTR) Enhancer: Regulation of LTR Activity and Virus Replication in Macrophages. J Virol 2004; 78(7): 3407-18.
27. Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489-519.
28. Schiltz RL, Shih DS, Rasty S, Montelaro RC, Rushlow KE. Equine infectious anemia virus gene expression: characterization of the RNA splicing pattern and the protein products encoded by open reading frames S1 and S2. J Virol 1992; 66(6): 3455-65.
29. Li F, Craigo JK, Howe L et al. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 2003; 77(13): 7244-53.
30. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73: 8356-8363.
31. Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004; 17: 17-26.
32. Mansfield K, Lang SM, Gauduin MC, et al. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol 2008; 82: 135-148.
33. Schmitz JE, Johnson RP, McClure HM, et al. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 2005; 79: 8131-8141.
34. Shen T, Liang H, Tong X, et al. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine 2006; 24: 738-749.
35. Hochhauser SJ, Weiss B. Escherichia coli mutants deficient in deoxyuridine triphosphatase. J Bacteriol 1978; 134(1): 157-66.
36. Gadsden MH, McIntosh EM, Game JC, Wilson PJ, Haynes RH. dUTP pyrophosphatase is an essential enzyme in Saccharomyces cerevisiae. EMBO 1993; 12(11): 4425-31.
37. el-Hajj HH, Zhang H, Weiss B. Lethality of a dut (deoxyuridine triphosphatase) mutation in Escherichia coli. J Bacteriol 1988; 170(3): 1069-75.
38. Elder JH, Lerner DL, Hasselkus-Light CS, et al. Distinct subsets of retroviruses encode dUTPase. J Virol 1992; 66(3): 1791-4.
39. Shao H, Robek MD, Threadgill DS, et al. Characterization and mutational studies of equine infectious anemia virus dUTPase. Biochim Biophys Acta 1997; 1339(2): 181-91.
40. Threadgill DS, Steagall WK, Flaherty MT, et al. Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant. J Virol 1993; 67(5): 2592-600.
41. Lichtenstein DL, Rushlow KE, Cook RF, et al. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J Virol 1995; 69(5): 2881-8.